2000 Sierra Point Parkway
Suite 400
Brisbane, CA 94005
United States
415 798 8589
https://www.tempesttx.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 17
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Stephen R. Brady J.D., LLM | CEO, President & Director | 923,24k | N/A | 1970 |
Mr. Nicholas Maestas | VP of Strategy & Finance and Secretary | 465,43k | N/A | 1981 |
Dr. Samuel Whiting M.D., Ph.D. | Executive VP & Chief Medical Officer | 667,65k | N/A | 1966 |
Mr. Justin Trojanowski | Corporate Controller, Treasurer & Principal Accounting Officer | N/A | N/A | 1988 |
Ms. Lindsay Young | Head of Human Resources | N/A | N/A | N/A |
Dr. Sharon Sakai Ph.D., RAC | Head of Regulatory & Quality | N/A | N/A | N/A |
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Tempest Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.